Table 2. Demographic, clinical, routine biochemical and genetic data of the subcohorts.
| PDND | PDD | p-values | |
| Individuals (f in %) | 62 (40.3) | 31 (35.5) | 0.65 |
| Age (years) | 68 (44–84) | 74 (54–88) | <0.0001* |
| AAO parkinsonism (years) | 60 (39–78) | 64 (48–84) | 0.008* |
| Duration parkinsonism (years) | 7 (1–23) | 11 (1–26) | 0.11 |
| Aao dementia (years) | 69 (50–80) | ||
| Duration dementia (years) | 5 (0–10) | ||
| H&Y stage (1–5) | 2 (1–3.5) | 2.25 (1–4) | 0.24 |
| BDI (0–63) | 8.5 (1–21) | 9 (2–29) | 0.77 |
| MMSE (0–30) | 28.5 (19–30) | 23 (10–26) | <0.0001* |
| UPDRS (0–199) | 7 (0–37) | 3 (0–43) | 0.60 |
| CSF Abeta1–42 (pg/ml) | 750 (269–1127) | 419 (141–737) | <0.0001* |
| CSF t-tau (pg/ml) | 195 (109–432) | 244 (61–927) | 0.18 |
| CSF p-tau (pg/ml) | 43 (26–72) | 42 (21–107) | 0.69 |
| ApoE4 (%) | 22.58 | 12.9 | 0.27 |
| GSK3B (A allele of SNPrs6438552) | 92.86 | 75.0 | 0.24 |
| HLA-DRA (A allele of SNPrs3129882) | 83.33 | 79.17 | 0.66 |
| HSPA5 (A allele of SNP rs430397) | 11.11 | 18.75 | 0.42 |
| SNCA (G allele of SNP rs356219) | 58.49 | 52.0 | 0.59 |
| STK39 (A allele of SNP rs4668049) | 27.45 | 39.13 | 0.32 |
Demographic, clinical and biochemical data of patients with Parkinson’s disease non-demented (PDND) and Parkinson’s disease with dementia (PDD) are presented with median (range) or percentage of total. P-values were determined using the Wilcoxon rank sum test or the Fisher’s exact test. Aao, age at onset; ApoE4, at least one Apolipoprotein E4 allele; BDI, Beck Depression Inventory; CSF, cerebrospinal fluid; f, female; GSK3B, Glycogen synthase kinase 3 beta; HLA-DRA, Human leucocyte antigen/Major histocompatibility complex, class II, DR alpha chain; HSPA5, Heat shock 70 kDa protein 5; H&Y, Hoehn & Yahr stage; MMSE, Mini-Mental State Examination; p-tau, phospho-tau; SNCA, Synuclein alpha; STK39, Serine threonine kinase 39; t-tau, total tau; UPDRS, Unified Parkinson’s Disease Rating Scale.